** Brokerage Guggenheim raises PT on ANI Pharmaceuticals
to $83 from $77, retains "buy" rating
** New PT represents a 47.7% upside to stock's last close
** Says, updating its model following the close of the Alimera acquisition
** On Monday, ANIP announced it completed its acquisition of Alimera Sciences , expanding its rare disease business
** Brokerage estimates FY24 product revenues of $34.4 mln for Alimera, including sales of $4.1 mln for the last ~2 weeks of Q3 2024, which will be recorded by ANIP
** Says deal to have positive impact on ANIP's outlook
** Average rating of 5 brokerages is equivalent to "buy"; median PT is $83
** Up to last close, stock up 1.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。